19 results about "Phosphorylethanolamine" patented technology

The invention relates to a flame-retardant skin-friendly polyurethane sponge with in-situ reaction and bio-enzyme catalysis synergism. The water-based polyurethane foam is prepared from the following components: polyether polyol, diphenylmethane diisocyanate or toluene diisocynate, a chain extender, a high-efficiency foam stabilizer, a high-efficiency composite catalyst, water and ethanolamine phosphate, ethanolamine phosphate is added into water in advance, and then all the raw materials are mixed for polymerization foaming; after curing, spraying a spraying liquid consisting of phosphoethanolamine, regenerated protein and transglutaminase to generate a nano protein film, and synchronously performing vacuum suction to keep sponge pores unblocked. The preparation method has the advantages that a small amount of ethanolamine phosphate is added before polymerization foaming to serve as a phosphorus-nitrogen synergistic flame retardant and also serve as a catalytic cross-linking agent to participate in a reaction during polymerization, biological enzyme is added for catalysis after curing is finished, and the skin-friendly PU sponge with excellent flame retardance is prepared through in-situ polymerization reaction and biological enzyme enzymatic polymerization cooperation, and the sponge performance is not affected; the raw materials of the flame retardant come from biomass products and are environment-friendly and safe.

The present invention relates to ophthalmic compositions comprising at least one substance of at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, megamine and derivatives thereof, and / or the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particularly preferred are choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g. Lecithin having a phosphatidylcholine content of > = 80% by weight, e.g. Soybean lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-alpha-glycerophosphorylcholine, phosphatidylcholine, phosphatidylethanolamine.

The invention relates to an exosome with high permeability and application of the exosome, and the surface of the exosome is connected with dioleoyl phosphatidylserine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylethanolamine and hirudin. The exosome constructed by the invention can improve the permeability of the skin, can carry active components to directly reach the skin epidermis and corium layer, is accumulated on the epidermis and corium layer, continuously provides nutrition for the skin, and fully exerts the skin care and beautifying effects.

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.

The invention discloses a strain of Chryseobacterium wanjuense C14, and a preparation method of the Chryseobacterium wanjuense C14. The invention further discloses application of the bacillus subtilis in inhibition of ralstonia solanacearum and application of the bacillus subtilis in degradation of straw. The Chryseobacterium sp. C14 can obviously inhibit the growth of pathogenic bacteria of tomato bacterial wilt, especially under the assistance of tomato rhizosphere metabolites such as O-phosphoethanolamine, mangiferin and L-tryptophan, the antibacterial effect of the Chryseobacterium sp. C14 is further enhanced, and the Chryseobacterium sp. C14 has higher environmental adaptability and prevention and treatment potential. The Chryseobacterium sp. C14 can also degrade protein, cellulose and hemicellulose at the same time, and can significantly promote the degradation of rice straw and corn straw. The Chryseobacterium sp. C14 has the functions of straw degradation and tomato ralstonia solanacearum inhibition, integrates a soil-borne disease biological control function and efficient straw degradation, and provides a green and efficient microbial new strategy for solving the problems of difficult straw treatment and difficult tomato bacterial wilt control in agricultural production.

The invention relates to a sample pretreatment method for pyrite elemental analysis. The method comprises the following steps: firstly, preparing a pretreatment agent: activating the surface of carboxymethyl chitosan by NHS / EDC, and then reacting with ethanolamine phosphate; secondly, a pyrite sample is taken and smashed into particles, the particles, NaOH, NaNO3 and a pretreatment agent are fully ground into powder, then the temperature is increased to 180-250 DEG C and then increased to 350-450 DEG C for heat preservation, sintered solids are transferred into a beaker, a hot nitric acid solution is added, the solids are dissolved through ultrasonic treatment, the solids are filtered into a volumetric flask after being cooled, and a to-be-tested sample is obtained after the volume is fixed through dilute nitric acid; according to the treatment method, use of a large amount of concentrated acid and perchloric acid is avoided, the reagent dosage is small, and environment friendliness is achieved; the recovery rate of 95% or above can be ensured when the treated sample is measured by instruments such as ICP-MS, the maximum RSD value does not exceed 5% compared with a standard value, and the accuracy is good.

The invention discloses a molecular marker related to the content of glyceryl phosphorylethanolamine in pig muscle and application of the molecular marker. The invention provides an application of a substance for detecting the genotype of an SNP site in a pig genome in at least one of the following applications: A1) detecting or assisting in detecting the content state of glyceryl phosphorylethanolamine of a to-be-detected pig; a2) breeding pigs with high content of glyceryl phosphorylethanolamine; a3) pig breeding; and A4) preparing a product for detection or auxiliary detection of the content state of the glyceryl phosphorylethanolamine of the to-be-detected pig. According to the invention, by detecting the genotype of the pig to be detected at the SNP site, early selection of the content of glyceryl phosphoryl ethanolamine in pig muscle can be realized, the production cost can be saved, the genetic progress can be accelerated, and the SNP site has great economic application value and scientific research value.

The present invention relates to ophthalmic compositions comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, particularly varenicline, mecamillamine, and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts thereof, and choline-containing phospholipids, salts and derivatives thereof. Of these, choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g., lecithin with a phosphatidylcholine content of 80% by weight or more, e.g., soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine are particularly preferred.

The application relates to a sample pretreatment method for pyrite element analysis. First, a pretreatment agent is prepared: carboxymethyl chitosan is activated on the surface through NHS / EDC, and then reacts with phosphoethanolamine to obtain the pretreatment agent; secondly, a pyrite sample is crushed into particles, and is fully ground into powder together with NaOH, NaNO3 and the pretreatment agent; then, the temperature is increased to 180-250 DEG C and then to 350-450 DEG C for heat preservation; the sintered solid is transferred into a beaker, hot nitric acid solution is added, ultrasonic is used to dissolve the solid, and after cooling, filtration is carried out into a volumetric flask, and dilute nitric acid is used for constant volume to obtain a sample to be tested. The treatment method avoids the use of a large amount of concentrated acid and perchloric acid, the reagent consumption is small, and the method is environment-friendly; the treated sample is determined by an ICP-MS instrument and the like, and the recovery rate can be ensured to be above 95%; compared with a standard value, the RSD value is not more than 5%, and the accuracy is good.

The invention provides a metabolic biomarker for diagnosing systemic lupus erythematosus and application of the metabolic biomarker, and belongs to the technical field of biological medicines. The metabolic biomarker is at least one metabolite of sasol, ceramide phosphate and homoveratric acid. A reagent for detecting the expression quantity of the metabolic biomarker can be used for preparing a product for diagnosing systemic lupus erythematosus. The invention determines that the expression quantities of metabolites such as 1-stearoyl-2-hydroxy-sn-glycerol-3-phosphoethanolamine, sasol, ceramide phosphate, homoveratric acid and the like in blood samples of an SLE patient and a healthy person have significant changes, so that the metabolite is put forward to be used as a biomarker for SLE disease diagnosis independently or in combination; the kit has the advantages of high accuracy, high sensitivity and high specificity, and provides a new target for diagnosis, intervention improvement and the like of SLE patients.

The application provides a metabolic marker combination for early kidney cancer diagnosis and application thereof, and belongs to the technical field of in vitro diagnosis. The metabolic marker combination for early kidney cancer diagnosis comprises a first combination or a second combination. The first combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, methylphosphatidylcholine 33:2e and triglyceride 54:7. The second combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, L-threonyl-L-aspartic acid, iminodiacetic acid, triglyceride 56:8, O-phosphoethanolamine, methylphosphatidylcholine 33:2e and triglyceride 54:7. By detecting the metabolic marker combination in a blood sample, it can be determined whether a patient has early kidney cancer, has high sensitivity and specificity, can realize precise screening of early kidney cancer, and provides important help for prevention and reduction of the incidence of kidney cancer.

The application discloses a combined immunization drug, a temperature-sensitive gel composition, a chemotactic factor particle and application thereof, and uses a mixed solution of an injectable temperature-sensitive polymer PLGA-PEG-PLGA, a chemotactic factor particle and an immune checkpoint inhibitor PD-1 monoclonal antibody to form a temperature-sensitive hydrogel beside a solid tumor at body temperature, and long-term controllable release of the chemotactic factor and aPD1, so as to enhance the targeting of adoptive T cells to the solid tumor and the resistance to immunosuppression in the tumor microenvironment. Through combination of the immunoregulatory temperature-sensitive gel and a tumor-penetrating peptide iRGD, the infiltration of the adoptive T cells to the solid tumor is enhanced, so that the solid tumor is efficiently treated. The chemotactic factor particle is constructed by using a distearoyl phosphoethanolamine-polyethylene glycol-N-hydroxysuccinimide modified chemotactic factor and an albumin carrier.

A use of gut microbiota or a metabolite thereof and / or an antibody or a derivative thereof in preparation of immunotherapeutic drugs for colorectal cancer. The gut microbiota comprises at least one of Alistipes shahii, Butyricimonas virosa, Desulfovibrio piger, Actinomyces humiferus, Odoribacter splanchnicus, Faecalibacterium prausnitzii, Phocaeicola plebeius, Eubacterium rectale, Oscillospiraceae bacterium, and Alistipes onderdonkii. The metabolite of the gut microbiota comprises at least one of O-phosphorylethanolamine, 5,6-dihydroxyindole-2-carboxylic acid, phosphatidylcholine (O-16:0_20:4), and 4-acetamidobutyric acid. The antibody comprises an IL-17A signaling pathway monoclonal antibody and / or a colorectal cancer-targeted monoclonal antibody.

The present disclosure relates to the production of oligosaccharides, especially Human milk Oligosaccharides (HMOs) using a genetically engineered cell which has decreased or total loss of function of phosphoglycerol transferase I and II and / or phosphoethanolamine transferase and / or glucans biosynthesis protein C to reduce oligosaccharide by-products and / or increase oligosaccharide production.

The application belongs to the technical field of feed additives, and particularly relates to application of cytidine diphosphate ethanolamine in preparation of products for promoting animal growth or improving animal muscle performance. The application obtains the key metabolite cytidine diphosphate ethanolamine related to animal muscle performance through multi-omics joint analysis screening, the key metabolite cytidine diphosphate ethanolamine is derived from an animal body, is a key intermediate in phosphatidylethanolamine (PE) biosynthesis, and participates in CDP-Etn pathway regulation. The cytidine diphosphate ethanolamine can be applied in feed, feed additives or health products in a specific adding mode and dose, is suitable for various breeding animals such as rodents, poultry and mammals, and can significantly improve average daily feed intake, body weight growth rate, increase chest muscle weight, improve chest muscle rate and enhance grip strength.

The present invention is directed to a method for detecting the presence or absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, comprising: (a) subjecting a test sample to mass spectrometry analysis and generating a mass spectrum output; wherein said test sample comprises a bacterial membrane or a fragment thereof, wherein the fragment comprises a non-Lipid A component; (b) identifying in said mass spectrum output a first defined peak indicative of the presence of Lipid A modified by phosphoethanolamine, wherein said first defined peak is a peak present in a mass spectrum output for Lipid A modified by phosphoethanolamine and wherein said first defined peak is absent from a corresponding mass spectrum output for native Lipid A; and (c) wherein the presence of said first defined peak indicates the presence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, and wherein the absence of said first defined peak indicates the absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic. This method is also used in a screening method to identify an inhibitor of cyclic cationic polypeptide antibiotic resistance in a bacterium. The matrix solution can contain 2,5-dihydroxybenzoic acid and aids in the selective extraction, co-crystallisation and ionisation of native Lipid A and / or modified Lipid A as an integral part of a bacterial membrane.

The application provides metabolic biomarkers for diagnosing systemic lupus erythematosus and application thereof, and belongs to the technical field of biological medicine. The metabolic biomarker is at least one metabolite of sarsasurine, ceramide phosphate and high quercetin acid. A reagent for detecting the expression amount of the metabolic biomarker can be used for preparing a product for diagnosing systemic lupus erythematosus. The application determines that the expression amounts of 1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, sarsasurine, ceramide phosphate and high quercetin acid metabolites in blood samples of SLE patients and healthy people change significantly, so the metabolites are proposed to be used as biomarkers for diagnosing SLE diseases alone or in combination, and the biomarkers have the advantages of high accuracy, high sensitivity and high specificity, and provide new targets for the diagnosis and intervention improvement of SLE patients.

A lipid nanoparticle and a method of delivering a nucleic acid encapsulated in the lipid nanoparticle to a cell or a subject. The lipid nanoparticle may contain 55-65 mol% of a cationic lipid to the total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 1-3 mol% of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle. The lipid nanoparticle may also contain 55-65 mol% of a cationic lipid to a total lipid amount of the lipid nanoparticle; 30-40 mol% of a sterol to the total lipid amount of the lipid nanoparticle; 4-6 mol% of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) to the total lipid amount of the lipid nanoparticle; and 1-5 mol% of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) to the total lipid amount of the lipid nanoparticle.

The invention relates to a nano preparation and a preparation method and application thereof, in particular to the technical field of biomedical materials. The nano preparation has a core-shell structure and comprises a core and a shell, the core comprises a photosensitizer and a glycometabolism inhibitor, the shell comprises an amphiphilic polymer, the photosensitizer is a near-infrared two-region fluorescent dye TTQ-BT-TPA, the glycometabolism inhibitor comprises lonidamine, the amphiphilic polymer comprises 1, 2, 4-trimethyl-1, 3-pentanediol monoisobutyrate, and the 1, 2, 4-trimethyl-1, 3-pentanediol monoisobutyrate is a near-infrared two-region fluorescent dye TTQ-BT-TPA. The composition is prepared from 1, 2-distearoyl-sn-glycerol-3-phosphoethanolamine-polyethylene glycol 2000 and 2-distearoyl-sn-glycerol-3 The invention provides a nano preparation. In the prior art, a traditional photodynamic therapy is limited in curative effect in a tumor anoxic zone due to dependence on oxygen, and tumor cells maintain a high-level anti-oxidation defense system due to metabolism reprogramming and are insensitive to ferroptosis; and the problem of poor synergistic effect caused by lack of accurate intervention on tumor metabolism and reduction of the yield of fluorescence and active oxygen in a photosensitizer aggregation state of an existing synergistic treatment system is solved.